WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124939
CAS#: 1628323-80-7 (free base)
Description: Rusfertide is an injectable peptide mimetic of hepcidin (hepcidin antimicrobial peptide; HAMP; putative liver tumor regressor; PLTR; liver-expressed antimicrobial peptide 1; LEAP-1) with potential use in the treatment of iron deficiency anemia and iron overload secondary to hematologic disorders.
Hodoodo Cat#: H124939
Name: Rusfertide
CAS#: 1628323-80-7 (free base)
Chemical Formula: C114H181N27O28S2
Exact Mass: 2,440.30
Molecular Weight: 2,441.980
Elemental Analysis: C, 56.07; H, 7.47; N, 15.49; O, 18.34; S, 2.63
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1628323-80-7 (free base) 2273884-08-3 (acetate)
Synonym: Rusfertide; Rusfertide [USAN]; XM71MYX0IQ; PTG-300FB; PTG-300
IUPAC/Chemical Name: N5-(4-((3S,6S,9S,15R,20R,23S,26S,29S,32S,37aS)-9-(4-aminobutyl)-29-benzyl-23-((S)-sec-butyl)-32-(2-carboxyethyl)-15-(((S)-1,6-diamino-1-oxohexan-2-yl)carbamoyl)-3-(3-guanidinopropyl)-6-(hydroxymethyl)-20-((S)-1-((3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl)pyrrolidine-2-carboxamido)-1,4,7,10,13,21,24,27,30,33-decaoxotetratriacontahydro-19H-pyrrolo[2,1-s][1,2]dithia[5,8,11,14,17,20,23,26,29,32]decaazacyclopentatriacontin-26-yl)butyl)-N2-palmitoyl-L-glutamine
InChi Key: JRVOBXXOZFTSRF-GVIPULMVSA-N
InChi Code: InChI=1S/C114H181N27O28S2/c1-7-9-10-11-12-13-14-15-16-17-18-19-26-46-90(145)125-79(113(168)169)47-49-89(144)121-53-32-29-42-76-99(154)133-80(58-71-36-22-20-23-37-71)101(156)132-78(48-50-93(148)149)111(166)140-55-34-44-87(140)107(162)130-77(43-33-54-122-114(118)119)100(155)136-84(64-142)104(159)129-75(41-28-31-52-116)98(153)123-63-92(147)127-85(105(160)128-74(97(117)152)40-27-30-51-115)65-170-171-66-86(106(161)138-95(69(5)8-2)109(164)131-76)137-108(163)88-45-35-56-141(88)112(167)83(59-72-38-24-21-25-39-72)135-102(157)81(60-73-62-120-67-124-73)134-110(165)96(70(6)143)139-103(158)82(61-94(150)151)126-91(146)57-68(3)4/h20-25,36-39,62,67-70,74-88,95-96,142-143H,7-19,26-35,40-61,63-66,115-116H2,1-6H3,(H2,117,152)(H,120,124)(H,121,144)(H,123,153)(H,125,145)(H,126,146)(H,127,147)(H,128,160)(H,129,159)(H,130,162)(H,131,164)(H,132,156)(H,133,154)(H,134,165)(H,135,157)(H,136,155)(H,137,163)(H,138,161)(H,139,158)(H,148,149)(H,150,151)(H,168,169)(H4,118,119,122)/t69-,70+,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,95-,96-/m0/s1
SMILES Code: [H][C@@]12CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CC(C)C)[C@@H](C)O)[C@@H](C)CC
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 2,441.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Pemmaraju N, Kuykendall A, Kremyanskaya M, Ginzburg Y, Ritchie E, Gotlib J,
Gerds A, Palmer J, Valone F, O'Connor P, Modi N, Gupta S, Hoffman R, Verstovsek
S. MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological
Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in
Patients With Polycythemia Vera. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl
2:S338-S339. doi: 10.1016/S2152-2650(22)01462-8. PMID: 36164011.
2: Handa S, Ginzburg Y, Hoffman R, Kremyanskaya M. Hepcidin mimetics in
polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.
Curr Opin Hematol. 2023 Mar 1;30(2):45-52. doi: 10.1097/MOH.0000000000000747.
Epub 2022 Dec 29. PMID: 36728649; PMCID: PMC9908837.
